A federal drug discount program created to help vulnerable patients may be doing anything but – and the hospital lobby is fighting to keep it that way
In 1992, Congress created the 340B Drug Pricing Program with a straightforward mission: help safety-net hospitals and clinics serving low-income and uninsured patients stretch their resources further. Pharmaceutical manufacturers would sell outpatient drugs at steep discounts to qualifying providers, and the savings would flow to vulnerable patients.
Over three decades later, the program looks very different from what Congress intended.
What the Program Became
More than 55,000 covered entities now participate in 340B. Purchases grew from roughly $6.6 billion in 2010 to approximately ten times that level by 2023, with large health systems coming to dominate the program. Under the current structure, a covered hospital buys a drug at the discounted 340B price, administers it to a patient, then bills the insurer or government payer at or near the full reimbursement rate — keeping the spread. Federal law does not require these savings be passed on to patients or reported in any meaningful detail.
340B hospitals buy discounted drugs and sell them at steep markups, sometimes more than ten times their acquisition cost.
A Case Study: Cleveland Clinic
A 2025 Senate HELP Committee report examined Cleveland Clinic directly. The findings were stark: the system’s total 340B benefit amounted to $933.7 million between April 2020 and June 2023. Despite that, Cleveland Clinic confirmed it does not pass 340B discounts directly to patients, citing no statutory requirement to do so. The hospital directed its 340B benefit to its operating budget, capital projects, and community programs with no detailed accounting of what share reached the low-income patients the program was designed to serve. Cleveland Clinic invested $1.05 billion in capital improvements during the same period and operates facilities in Abu Dhabi, London, and Toronto, all while benefiting from federal tax-exempt status and taxpayer-subsidized drug pricing.
The Senate report concluded that transparency and oversight failures prevent 340B discounts from translating to better access or lower costs for patients, and called on Congress to require detailed annual reporting on how 340B revenue is used.
What the Administration Proposed
Rather than eliminating 340B, the Trump administration proposed shifting from a discount model to a rebate structure that would create a clearer paper trail — documenting how much in discounts was generated and where the money ultimately went.
In August 2025, HRSA published a Federal Register notice launching the 340B Rebate Model Pilot Program. Covered entities would pay the drug’s wholesale acquisition cost upfront, then submit a rebate claim within 45 days of dispensing. The goal was simple: a transactional record linking each dispensing event to a qualifying patient, curbing duplicate discounts, and generating data to verify savings were reaching the right people.
What Happened Next
The pilot never launched. A federal court issued a nationwide injunction in December 2025, finding HRSA’s administrative record inadequate. The government appealed, then withdrew. By February 2026, the pilot was formally vacated. HRSA subsequently published a Request for Information drawing over 5,500 public comments, and has signaled it has not abandoned the rebate concept.
The Bottom Line
A program that resists the very transparency needed to prove it is helping the poor deserves scrutiny. If 340B savings are truly flowing to low-income patients, documentation should be welcomed, not litigated. The question before policymakers is simple: should federal discount programs be required to show their work? For the patients this program was built to serve, and the taxpayers funding the system around them, the answer must be yes.
